NCT06495203View on ClinicalTrials.gov

A Study to Understand the Usage of an Artificial Intelligence Technology Called DARWEN for Eye Disorders and to Find Out the Factors Influencing Treatment Frequencies in People With nAMD and RVO

CompletedOBSERVATIONAL
Enrollment

1,350

Participants

Timeline

Start Date

November 2, 2023

Primary Completion Date

February 29, 2024

Study Completion Date

February 29, 2024

Conditions
Neovascular Age-related Macular DegenerationRetinal Vein Occlusion
Interventions
DRUG

anti-VEGF treatment

Follow clinical practice/administration

Trial Locations (1)

Unknown

Bayer, Mississauga

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT06495203 - A Study to Understand the Usage of an Artificial Intelligence Technology Called DARWEN for Eye Disorders and to Find Out the Factors Influencing Treatment Frequencies in People With nAMD and RVO | Biotech Hunter | Biotech Hunter